NGL Fine-Chem Limited is engaged in pharmaceutical business. The Company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. Its products include in Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and finished dosage form categories. The APIs animal health products include Homidium Chloride, Clorsulon, Parvaquone, Carprofen, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Amitraz, Praziquantel, Flunixin Meglumine, S-Methoprene, Imidocarb Dipropionate and Nitroxynil. The APIs human health products include Nitazoxanide, Atovaquone, Febuxostat and Ranolazine. The Intermediates products include 4 Aminobenzamidine Dihydrochloride, 3-Aminobenzamidine Dihydrochloride, Aceturic Acid and 3-Trichlorovinyl Aniline Hydrochloride. The Finished dosage form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. The Company has manufacturing plants located around Mumbai.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.